Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - infliximab - injection, powder, for solution - 100 mg/vial - infliximab 100 mg/vial

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - infliximab - powder for solution for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - infliximab - powder for solution for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - infliximab - powder for solution for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - infliximab - powder for solution for infusion - 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cilag ag - infliximab - powder lyophilized for concentrate for solution for infusion - 100mg

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - infliximab - powder for concentrate for solution for infusion - infliximab 100 mg/vial - infliximab - * rheumatoid arthritis:remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:• adult patients with active disease when the response to disease modifying antirheumatic drugs (dmards),including methotrexate, has been inadequate.• adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards.in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x ray,has been demonstrated.* ankylosing spondylitis:remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.* psoriatic arthritis:remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous dmard therapy has been inadequate.* remsima should be administered:• in combination with methotrexate• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease.* psoriasis:remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet a (puva)* adult crohn’s disease remsima is indicated for treatment :• of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.• treatment of fistulising, active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).* ulcerative colitis• remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric crohn’s diseaseremsima is indicated for treatment of severe, active crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. infliximab has been studied only in combination with conventional immunosuppressive therapy.paediatric ulcerative colitisremsima is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 mp or aza, or who are intolerant to or have medical contraindications for such therapies.

Singapore - English - HSA (Health Sciences Authority)

celltrion healthcare singapore private limited - infliximab - injection, powder, lyophilized, for suspension - infliximab 100mg/vial

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - infliximab (pf-06438179) - injection, powder, lyophilized, for solution - infliximab (pf-06438179) 100mg / vial

Israel - English - Ministry of Health

j-c health care ltd - infliximab - powder for concentrate for infusion - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :- crohn's disease: treatment of moderate to severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy - ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - psoriatic arthritis : remicade is indicated for : treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease. - rheumatoid arthritis: remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. patients with severe active and progressive disease not previously treated with methotrexate or other dmards. in this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - psoriasis: remicade is indicated for: treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or puva. - ulcerative colitis: remicade is indicated for: treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-mp or aza or who are intolerant to or have medical contraindications for such therapies.- paediatric ulcerative colitis: remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 mp or aza, or who are intolerant to or have medical contraindications for such therapies